Valsartan case containing carcinogenic substances will bring negative impacts
Started with the Valsartan case, conflicts between doctors and pharmacists have led to discussions about rebates for pharmaceutical companies.
Doctors have opposed to the international proprietary names – this has been argued by them for a while – because they could not trust bioequivalently tes...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
